Studies in experimental models and controlled patient trials indicate that opioids are effective in managing neuropathic pain. However, side effects secondary to their central nervous system actions present barriers to their clinical use. Therefore, we examined whether activation of the peripheral mu-opioid receptors (MORs) could effectively alleviate neuropathic pain in rats after L5 spinal nerve ligation (SNL). Systemic loperamide hydrochloride (0.3-10 mg/kg, s.c.), a peripherally acting MOR-preferring agonist, dosedependently reversed the mechanical allodynia at day 7 post-SNL. This anti-allodynic effect produced by systemic loperamide (1.5 mg/kg, s.c.) was blocked by systemic pretreatment with either naloxone hydrochloride (10 mg/kg, i.p.) or methyl-naltrexone (5 mg/kg, i.p.), a peripherally acting MOR-preferring antagonist. It was also blocked by ipsilateral intraplantar pretreatment with methyl-naltrexone (43.5 lg/50 ll) and the highly selective MOR antagonist CTAP (5.5 lg/50 ll). However, this anti-allodynic effect of systemic loperamide was not blocked by intraplantar pretreatment with the delta-opioid receptor antagonist naltrindole hydrochloride (45.1 lg/50 ll). The anti-allodynic potency of systemic loperamide varied with time after nerve injury, with similar potency at days 7, 28, and 42 post-SNL, but reduced potency at day 14 post-SNL. Ipsilateral intraplantar injection of loperamide also dose-dependently (10-100 lg/50 ll) reversed mechanical allodynia on day 7 post-SNL. We suggest that loperamide can effectively attenuate neuropathic pain, primarily through activation of peripheral MORs in local tissue. Therefore, peripherally acting MOR agonists may represent a promising therapeutic approach for alleviating neuropathic pain. Ó
Introduction
Chronic non-malignant pain that develops after a peripheral nerve injury is often challenging to treat and refractory to current pharmacotherapies. Nevertheless, several studies in experimental models and controlled patient trials suggest that mu-opioid receptor (MOR) agonists are effective at attenuating neuropathic pain [30, 35, 36, 38, 50] . However, side effects (respiratory depression, sedation, cognitive dysfunction, addiction, and abuse) and toxicity secondary to their central nervous system (CNS) actions present substantial barriers to their clinical use, especially with high doses or chronic use [15, 30, 39] .
Opioid receptors synthesized in dorsal root ganglion (DRG) neurons are transported to their central and peripheral terminals in the superficial dorsal horn and peripheral tissues, respectively [8, 17, 50] . Although MORs located in the CNS are the primary sites for the anti-nociceptive actions of systemically administered morphine, peripheral MORs may become increasingly important for the anti-allodynic/anti-hyperalgesic
